Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Clinical trial NCT06899126 · RECRUITING
Trial details
- NCT number
- NCT06899126
- Sponsor
- Daiichi Sankyo
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-24
- Primary completion
- 2030-04-24
- Enrollment
- 686
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.